0001778016 us-gaap:CommonStockMember 2025-01-01 2025-12-31 0001778016 nbp:ADRMember 2025-01-01 2025-12-31 0001778016 2025-01-01 2025-12-31 0001778016 2025-12-31 0001778016 dei:BusinessContactMember 2025-01-01 2025-12-31 shares 0001778016 true true FY 20-F/A false true 2025-12-31 --12-31 2025 false false 001-39173 NovaBridge Biosciences E9 2440 Research Boulevard, Suite 400 Rockville Rockville MD MD 20850 20850 US Kyler Lei 2440 Research Boulevard, Suite 400 US (240 745-6330 American depositary shares, each ten(10) American depositary shares representing twenty-three (23) ordinary shares NBP NASDAQ Ordinary shares, par value $0.0001 per share NASDAQ 265377891 No No Yes Yes Non-accelerated Filer false true false U.S. GAAP false This Amendment No. 1 (“Amendment No. 1”) to our annual report on Form 20-F for the fiscal year ended December 31,2025 originally filed with the U.S. Securities and Exchange Commission on April 7, 2026 (the “Original Filing”) is being filed for the sole purpose of correcting certain inadvertent errors in previously reported beneficial ownership information. The corrected information does not affect the Company’s audited financial statements filed with the Original Filing.In addition, pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, the certifications pursuant to Section 302 and Section 906 of the Sarbanes-Oxley Act of 2002 have been re-executed as of the date of, and are re-filed as part of, this Amendment No. 1 as Exhibits 12.1 and 12.2.Other than expressly set forth herein, this Amendment No. 1 does not, and does not purport to, amend or restate any other information contained in the Original Filing nor does this Amendment No. 1 reflect any events that have occurred after the Original Filing was filed.